Search clinical trials for: Bioequivaelnce Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended Release Tablets

Total 27364 results

Corcept Therapeutics

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
Mylan Pharmaceuticals Inc

Completed

Fed Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
Vallon Pharmaceuticals, Inc.

Completed

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (SEAL)

ADHD | Narcolepsy

United States
Vallon Pharmaceuticals, Inc.

Completed

Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)

ADHD | Narcolepsy

Canada
Acorda Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. (MILESTONE℠)

Post-Ischemic Stroke

United States, Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Ranbaxy Inc.

Completed

Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions

Healthy
Ranbaxy Inc.

Completed

Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions

Healthy
Actavis Inc.

Completed

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions

Healthy

United States
Actavis Inc.

Completed

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

Healthy

United States
Medical University of Warsaw
Human Biome Institute S.A.

Active, not recruiting

Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease (EFFACE-PD)

Parkinson Disease

Poland
Kaohsiung Veterans General Hospital.

Unknown

Comparing the Efficacy of 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth Therapy

Helicobacter Pylori Infection

Taiwan
Cancer Institute and Hospital, Chinese Academy...
Beijing Huanxing Cancer Hospital

Recruiting

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Metastatic Breast Cancer

China
Guangzhou General Hospital of Guangzhou Military...

Completed

The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation

Pain

China
Rigshospitalet, Denmark
Odense University Hospital; Hvidovre University Hospital; Bispebjerg Hospital; Herlev... and other collaborators

Unknown

Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism (GRASS)

Graves' Hyperthyroidism

Denmark
Medical University of Vienna
Polymun Scientific, Vienna, Austria

Completed

Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity

Inflammation

Austria
Stryker Craniomaxillofacial
Qmed Consulting A/S

Enrolling by invitation

Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness

Craniofacial Abnormalities | Cranioplasty | Craniofacial Injuries

Germany, Spain, United States, Austria, France, United Kingdom
National Healthcare Group, Singapore
University of Pennsylvania; Nanyang Technological University; Alexandra Hospital and other collaborators

Completed

Supplements and Social Skills Intervention Study (SASSI)

Attention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant Disorder

Singapore
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
Pharma Nueva

Not yet recruiting

Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions (BE24-005)

Healthy Vollunteer
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
International Bio service

Not yet recruiting

The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions

Healthy Volunteer
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Benha University

Recruiting

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

Nocturnal Enuresis

Egypt
Fudan University
Peking Union Medical College Hospital

Recruiting

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Endometrial Neoplasm Malignant Stage I

China
XenoPort, Inc.

Recruiting

An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS (RLS)

RLS

United States
XenoPort, Inc.

Recruiting

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS (RLS)

RLS

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Genovate Biotechnology Co., Ltd.,

Completed

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

Intermittent Claudication

United States
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Tris Pharma, Inc.
Premier Research Group plc

Completed

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

ADHD

United States
Genovate Biotechnology Co., Ltd.,

Completed

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Intermittent Claudication

United States
Genovate Biotechnology Co., Ltd.,

Terminated

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Intermittent Claudication

United States
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Yang I. Pachankis

Completed

Medicine-induced Cardiac Hemodialysis on COVID-19

Renal Dialysis | Vaccines | Infection Viral | Severe Acute Respiratory Syndrome-related Coronavirus | Myocarditis Allergic

China

3

Subscribe